CELL CRYOPRESERVATION MARKET ANALYSIS

Cell Cryopreservation Market Size and Trends

Global cell cryopreservation market is estimated to be valued at USD 10.10 Bn in 2024 and is expected to reach USD 43.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 23% from 2024 to 2031.

Discover market dynamics shaping the industry: Request sample copy

Growing prevalence of chronic diseases coupled with rising investments in R&D of regenerative medicine can drive the global cell cryopreservation market growth.The market is witnessing various innovations that aid in commercialization and uptake of cell cryopreservation technologies. There has been an increased focus on developing techniques that can better preserve cell viability and functionality post-thaw. Cryopreservation of stem cells and genetically modified cells can offer opportunities for applications in drug discovery, personalized medicine and disease modeling over the forecast period.

Growing demand for stem cell research

Global cell cryopreservation market is expected to witness growth due to rising demand for stem cell research activities. Stem cells are used in developing new treatments for chronic and life-threatening diseases like cancer, diabetes, cardiac ailments and neurodegenerative conditions. Cryopreservation plays a crucial role in stem cell research as it allows viable storage and transportation of stem cells for extended periods of time. Researchers are continuously working on utilizing the unique capabilities of stem cells such as differentiation and regeneration for developing cell-based and targeted therapies. Significant investments are being made by both public and private players to advance stem cell science. For instance, the National Institutes of Health in the U.S. allocated millions of dollars funding for stem cell initiatives. Several biopharma companies have also ramped up their R&D efforts focused on stem cell therapies. With the progress of stem cell research, the requirements from cell cryopreservation expands in terms of higher sample volumes, more robust infrastructure and stricter regulatory compliances. Researchers need reliable preservation of different types of stem cells over extended durations for various applications ranging from basic research to clinical translation. For instance, in January 2024, a stem cell therapy created by UC Davis Health researchers demonstrated encouraging results in preclinical trials for treating Crohn’s disease.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Advancements in regenerative medicine

Technological advancements in the field of regenerative medicine can drive the market growth. Regenerative therapies aim to repair or replace damaged cells, tissues and organs through stimulating the body's innate healing response. Some key areas witnessing ground-breaking progress include tissue engineering, organ engineering and development of artificial organs. Several clinical trials are exploring the application of tissues grown from cryopreserved cell sources such as skin, bone marrow and heart valves for reconstructive procedures. Emerging field of 3D bioprinting also relies on cryopreserved cell viability for printing transplantable organs and implantable tissues. For example, scientists have successfully 3D printed heart patches, liver tissue and bone structures using living cells.

Key Takeaways from Analyst:

Global cell cryopreservation market growth is driven by increasing investments in stem cell research by both public and private organizations.  Stem cell therapies are used in the treatment of many incurable diseases, and this increases focus on developing stem cell biobanks. Rising prevalence of chronic diseases also boosts demand for cryopreservation of various cell types for future therapeutic use.

High cost of establishment and maintenance of stem cell banks can hamper the market growth. Safety concerns regarding long term storage of viable cells and tissues can also hamper the market growth. Regulations for stem cell research varies globally, and this can hamper the market growth.

North America dominates the global cell cryopreservation market, owing to presence of advanced research infrastructure and supportive regulatory environment in the region. However, Asia Pacific is likely to emerge as the fastest growing regional market. Countries like China, Japan and India witness rapid development of their biotech and biopharma industries, which boosts adoption of cell cryopreservation solutions. Increasing R&D investments in regenerative medicine and growing awareness about storage of cord blood stem cells can offer lucrative opportunities for market players.

Market Challenges: High cost of establishment and operations

The high cost related to establishing and operating a cell cryopreservation facility can hamper the global cell cryopreservation market growth. Setting up a cell cryopreservation lab requires sizable capital investments in advanced cryogenic equipment like controlled-rate freezers, liquid nitrogen storage tanks, and automated temperature monitoring systems. These equipment and technologies are highly sophisticated and expensive. For instance, a medium size -80°C mechanical freezer costs US$ 25,000 while an industrial sized liquid nitrogen storage tank costs U$ 100,000. Ongoing operational expenses of maintaining cryogenic temperatures and storing the cells long-term further increase costs. Costs of liquid nitrogen re-fills, regular equipment servicing, hiring specialized technicians to handle cryopreservation procedures increases the operating expenses. For many smaller research labs and hospitals, these substantial start-ups and running costs of cryopreservation can be a deterrent. While these recognize the merits of cryopreserving stem cells, tissue samples or other biologically significant cells, the investments needed restrict wider adoption of cell cryopreservation technique. For example, according to the data from the World Bank, average GDP per capita in developing countries like Kenya was around US$ 1,800 in 2020, making very large capital expenditure difficult. Similarly, public health spending as a share of GDP was only 4% in Kenya during the same period. Therefore, high initial capital and running costs reduce the viability of setting up cell cryopreservation facilities in such resource-strapped environments.

Market Opportunities: Rise in adoption of personalized medicine

Rising adoption of personalized medicine can offer opportunity for global cell cryopreservation market growth. Personalized medicine involves tailoring medical treatment to an individual patient's molecular profile and needs. With advancements in fields like genomics, high-throughput technologies and bioinformatics, doctors are now able to more accurately diagnose diseases, monitor disease progression and develop targeted treatment plans based on a patient's own genetic and molecular characteristics. This shift towards personalized healthcare necessitates long-term preservation and storage of individual patient's cells for continued research and future therapeutic applications if needed. Cell cryopreservation, which involves freezing cells at extremely low temperatures using cryoprotectants, provides an efficient way to bank individuals' cells for extended periods of time. Examples include stem cells collected from umbilical cord blood or adipose tissue which can be cryopreserved and stored in biobanks for potential future use in regenerative therapies. As awareness about benefits of personalized medicine grows and genomics-driven diagnostics and treatments become more mainstream, there will be huge demand for cryopreservation services from healthcare providers, biobanks and patients themselves who want to store their own cells and bio-samples. According to the World Marrow Donor Association, over 35 million umbilical cord blood units have been cryopreserved globally in public and private biobanks in 2021.

Discover high revenue pocket segments and roadmap to it: Request sample copy

By Product Type- Demand from biopharmaceutical and research institutes drive equipment segment growth

In terms of product type, equipment segment is estimated to contribute the highest market share of 60.1% in 2024, owing to increasing demand from biopharmaceutical and research institutes. The essential cryopreservation equipment required for cell and tissue storage and processing such as freezers, liquid nitrogen tanks, cryogenic vials, and others witnesses huge adoption. . Cell-based research activities are rising globally due to increasing funding into regenerative medicine and immunotherapy research. Manufacturers are developing advanced freezers with improved temperature control, storage capacity and safety features to accommodate the needs of large sample storage in medical research facilities and biobanks. Customized equipment solutions incorporating automation, tracking systems and cloud-based monitoring are also gaining popularity. The capability to protect and transport cell samples safely over long distances has expanded the geographical scope of research collaborations. This rising research intensity and complexity of cell-based applications can drive the segment growth.

By Application- Expanding applications of stem cells drives its dominance

In terms of application, stem cells segment is estimated to contribute the highest market share of 30.2% in 2024. Stem cells are increasingly employed in regenerative therapies for treating chronic diseases. Successful stem cell treatments for leukemia, blood disorders and cartilage injuries have translated into larger patient pools worldwide. Umbilical cord stem cells offer treatment hope for cerebral palsy, autism and multiple sclerosis. Advancements are also being made in employing them for heart failures, diabetes and Parkinson's disease. Several clinical trials are testing stem cell therapies for Alzheimer's, spinal cord injury and macular degeneration. Along with hospitals, stem cell biobanks are organizing to bank and supply well-characterized stem cell lines to drug developers.

By End User- Biological sample needs of biopharmaceutical industry

In terms of end user, biopharmaceutical & pharmaceutical companies segment is estimated to contribute the highest market share of  40.2% in 2024. The biopharmaceutical industry is among the major advocates for cell cryopreservation owing to its extensive R&D utilizing cell lines, primary cells and stem cells. Successful commercialization of cell and gene therapies along with growing development pipelines have boosted demand for supporting analytical and preservation infrastructure. Biopharmaceutical firms extensively utilize cryopreserved cells for pre-clinical safety and efficacy assessments during drug development. Biological sample reproducibility and integrity assume paramount importance as the industry deals with stringent regulations. These also bank deposited cell lines with cryobanks for future proprietary use. As targeted therapies gain traction, the need for developing and verifying biological markers on primary patient-derived material is rising. This propels biopharmaceutical firms to bank large volumes of clinical samples for biomarker discovery programs.

Regional Insights

To learn more about this report, Request sample copy

North America has established itself as the dominant regional market with an estimated market share of 40.2% in 2024 for cell cryopreservation. With a highly developed healthcare infrastructure and significant R&D investments, the U.S. and Canada have built a strong footprint in life sciences technologies. Major industry players have set up their headquarters in the region to leverage talent and funding opportunities. North American research institutions also have extensive collaborations with private sector cryopreservation solution providers. The favorable regulatory environment further encourages clinical translation of new cryopreservation methods.

Asia Pacific is poised to emerge as the fastest growing regional market. Countries like China, India, Japan and South Korea are making immense progress in life sciences capabilities. Rising healthcare expenditures and expanding patient volumes are propelling investment into biobanking and regenerative medicine applications of cryopreservation. Local companies are actively partnering with multinational corporations to upgrade technology and management expertise. Governments provide subsidies to boost the commercialization of indigenous innovations. With a burgeoning middle class, there will be huge demand for advanced treatments involving cryopreserved cells and tissues in Asia Pacific.

Market Report Scope

Cell Cryopreservation Industry News

• In June 2023, BioLife Solutions, Inc., a prominent provider of bioproduction tools and services for cell and gene therapy, introduced a new large-capacity controlled-rate freezer (CRF) as part of its expanded product line. This addition, which now includes three different form factors, addresses a significant demand from customers seeking increased production capacity for cell therapies on tabletop freezers.
• In 2022, AMSBIO, a leading provider of quality life science research reagents and services. launched 'STEM-CELLBANKER EX,' an innovative cryopreservation product designed to accelerate the development of cell therapy products. This chemically defined cryopreservation medium includes inactive ingredients approved for intravenous use, providing a premium solution for preserving stem cells. This advancement is poised to significantly enhance research and development in the field of cell therapy.
• In May 2022, Bristol Myers Squibb, global biopharma company received European Commission approval for Breyanzi, a CAR T cell therapy targeting CD19, to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more prior treatments. This authorization applies to all European Union member states.
• In July 2020, Kite, a biotechnology company, gained FDA accelerated approval for Tecartus, another CAR T cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma (MCL). Tecartus was approved following a priority review and FDA Breakthrough Therapy Designation, based on results from the ZUMA-2 study. The study showed a 87% response rate to a single infusion of Tecartus, with 62% achieving a complete response. Notably, 18% experienced Grade 3 or higher cytokine release syndrome (CRS) and 37% had Grade 3 or higher neurologic toxicities among those evaluated for safety.

*Definition: The global cell cryopreservation market consists of companies that provide cell and tissue cryopreservation services and products for research and therapeutic applications. These supply cryopreservation media, storage containers, cooling equipment, and sample management software that allow biological samples such as stem cells, cells, and tissues to be preserved at very low temperatures (-80°C or below) for long periods of time. This preservation allows samples to be stored and maintained for future use in applications like regenerative medicine, drug discovery, and biobanking.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Cryoprotectant Agents
  • Equipment
•  Application Insights (Revenue, USD Bn, 2019 - 2031)
  • Stem Cells
  • Oocytes and Embryotic cells
  • Sperm Cells
  • Hepatocytes
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Biopharmaceutical & Pharmaceutical Companies
  • Research Institutes
  • Biobanks
  • IVF clinics
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • GE Healthcare
  • Lonza Group Ltd.
  • STEMCELL Technologies Inc.
  • BioLife Solutions, Inc.
  • Cryolife, Inc.
  • Organ Recovery Systems Inc.
  • Custom Biogenic Systems
  • Sartorius AG
  • Takara Bio Inc.
  • Chart Industries, Inc.
  • Biocision, LLC
  • Cardinal Health, Inc.
  • Helmer Scientific